Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. - Wikidata - wikimedia - TriplyDB

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.

http://www.wikidata.org/entity/Q33241590

about

Axitinib for the management of metastatic renal cell carcinoma 3D microtumors in vitro supported by perfused vascular networks.Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors.A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS.ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways.Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib.Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.Novel therapeutic strategies for targeting liver cancer stem cells.The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway.Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC Targeted therapy in hepatocellular carcinoma Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future HCC and angiogenesis: possible targets and future directions ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer.Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer TSLP signaling network revealed by SILAC-based phosphoproteomics Spectrophotometric and molecular modelling studies on in vitro interaction of tyrosine kinase inhibitor linifanib with bovine serum albumin Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer.Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells.Inhibition of angiogenesis and invasion in malignant gliomas.Monitoring tumor response to linifanib therapy with SPECT/CT using the integrin αvβ3-targeted radiotracer 99mTc-3P-RGD2.Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer.ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies.Bench to bedside targeting of FLT3 in acute leukemia.Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.

P2860

Q24613720-5DDB576E-16B9-4DE1-8E87-987C8AADE70B Q27317186-DB327049-5EAA-46CE-B81A-2BF25CD90B59 Q27693185-4B4CC467-F070-4F05-8480-7B8A189D794F Q28072021-EA91B64B-105A-4C39-B6B0-D5D5E1C4A6C1 Q28075305-FE3FC7AE-E368-4DBB-83A8-260888FDE03F Q28477269-2519D6DC-F4E8-4408-B65C-B126F40861BB Q30454128-1FC5F59B-E068-4036-8920-CB0BFB91ABAD Q33415143-51D07FFF-B8F8-468F-8915-D9CC3ED6C29E Q33440505-DB5CE261-7DAC-47C5-B6E6-42B9790EAEE1 Q33723414-CAB900CC-15E5-41D4-B7A6-F13ECDC42F00 Q33786788-973004C6-8483-4E47-9DF5-6E7885600AEA Q33817062-200A24DA-C226-439D-B073-AE2B7B1D7B33 Q34206601-93910FEC-2218-4146-ACF2-0172E3126F44 Q34366102-F1C527DA-B6D0-491F-A8B6-17D3F048F1F6 Q34591403-BA4E589B-0885-4F3C-82A3-D35BF4F4BB51 Q34940971-A7C47688-7B0C-41DD-887B-9BFF5F942804 Q35038725-D96A4D36-CE45-4835-904A-D57D8915FDE9 Q35050210-2F952A6E-6E71-4C82-805B-F7152F2C31AF Q35207561-EBA58562-C17B-4C37-A190-2BF13E372A8F Q35501246-203E6B8F-6BE5-454B-BAA2-93CC5B05CE02 Q35640101-143DBB12-1069-46C4-BACE-20CD98EBFD0E Q35698574-6B631FEC-0E20-43DE-BFCE-CE799E898C94 Q35751114-2F17FC5F-232C-4931-8F1C-179AC11504AB Q35759606-A1A66215-751E-4F9D-8073-297B84E97F71 Q35996229-5E94BDBF-146D-4D43-B94C-AC250B9A0478 Q36075407-9B48F4DB-DD33-469D-A805-4C3514CCD448 Q36161541-B49EDDCC-EB00-4D37-9F0D-22B615768D46 Q36208936-AF945B50-B3F4-4C9D-A846-86EECA8264A4 Q36349729-52A22E33-E12F-4F73-9CC4-1660DDD8A3FA Q36594240-FEC3C854-4369-4165-959D-746BBB160B35 Q36967036-0FDC5778-2DC5-4337-AB57-9FD288E3D6FA Q37004664-E72EF671-384F-4023-BB39-5690454FA6C1 Q37027027-5D8DDAF0-D71F-4089-BA73-24A0D8A9CE23 Q37076592-55BE7611-BB08-4A75-9262-87E59D2F7DB1 Q37312735-D57F04A2-03E9-4C17-B0E8-59BDF3ED13B5 Q37495206-7519FE4C-ACAC-4FB0-8007-F4A5AC4D140E Q37565213-D652F7CD-6D0D-435C-820F-AE75BA0C80F1 Q37632167-0B6CA17B-BCBC-4C31-A163-2249C47C6B56 Q37724957-C8828626-25B8-45A0-8CE7-DBE534AA8726 Q37761374-D362DFE8-9EE8-4E52-B8D7-CF7F0AD22E92

P2860

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.

http://www.wikidata.org/entity/Q33241590

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.

@ast

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.

@en

type

label

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.

@ast

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.

@en

prefLabel

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.

@ast

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.

@en

P1433

Q33241590-F9D40264-177A-4679-90CA-070E5F466F76

P1476

Q33241590-EE99CEAC-0996-41EB-A885-6C7E77C555B0

P2093

Q33241590-07E1F039-7896-4412-8DD6-BCD942292327

Q33241590-0800718A-6C3F-4229-AF8E-A5941D382307

Q33241590-19DD0BF6-8666-4F43-BEFD-748AE294AC5A

Q33241590-1EADDB20-7A98-409C-BA4A-CFEBF1D6B4F9

Q33241590-22219880-1B2D-465B-823F-9035097E49B7

Q33241590-29A19188-85CF-448C-A9FE-66FDE11430D8

Q33241590-2ED57423-27A4-41BF-BE51-BC9CDEBF6F0B

Q33241590-329A03BE-9799-4A40-947E-425C3B47F18C

Q33241590-33AAA142-7343-426A-96A5-3EA56DCC6868

Q33241590-39CFA768-6A6E-41C9-8B08-7FE11F831AA5

P304

Q33241590-439C4BAE-E239-4497-91EB-533DB4FAEA98

P31

Q33241590-649C837B-9BEA-493F-8707-45F25F46BC76

P356

Q33241590-B3E36032-AC79-41E3-8682-87499312B721

P433

Q33241590-EC852DC0-7200-4D08-9F69-208C40DBB667

P478

Q33241590-BA70A080-20DC-425E-81AE-57A6FFC883EB

P577

Q33241590-6168A3F7-2677-4161-8A8D-8D9C5CB25EFD

P698

Q33241590-04BCBBB8-8471-46DE-932D-54E742B1A8CB

P921

Q33241590-55FF142D-2213-48F2-8290-EA5B6C9873D7

P356

1535-7163.MCT-05-0410

P1433

Molecular Cancer Therapeutics

P1476

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.

@en

P2093

Amanda L Niquette

http://www.w3.org/2001/XMLSchema#string

Baole Wang

http://www.w3.org/2001/XMLSchema#string

Cherrie K Donawho

http://www.w3.org/2001/XMLSchema#string

Daniel H Albert

http://www.w3.org/2001/XMLSchema#string

David R Reuter

http://www.w3.org/2001/XMLSchema#string

Eric F Johnson

http://www.w3.org/2001/XMLSchema#string

Gail T Bukofzer

http://www.w3.org/2001/XMLSchema#string

J Owen McCall

http://www.w3.org/2001/XMLSchema#string

Jason A Stavropoulos

http://www.w3.org/2001/XMLSchema#string

Jennifer J Bouska

http://www.w3.org/2001/XMLSchema#string

P304

995-1006

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-05-0410

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16648571

http://www.w3.org/2001/XMLSchema#string

P921